NU6300 |
| Katalog-Nr.GC32829 |
NU6300 ist ein kovalenter, irreversibler und ATP-kompetitiver CDK2-Inhibitor mit einem IC50-Wert von 0,16 μM. NU6300 kann für die Erforschung des eukaryotischen Zellzyklus und der Transkription verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2070015-09-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NU6300 is the first covalent ATP-competitive CDK2 inhibitor.IC50 value:Target: CDK2in vitro: NU6300 is a covalent CDK2 inhibitor that illustrates the potential of using vinyl sulfones to mediate irreversible inhibition. NU6300 blocks the inhibitor binding site. The effect was time dependent and relatively slow, with less than 50% reduction of the apparent binding capacity in 20 hr.
[1]. Anscombe E, et al. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chem Biol. 2015 Sep 17;22(9):1159-1164.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *